PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHOR	ITY	•	an.
Го:			PCT Canalation
			RITTEN OPINION OF THE SONAL SEARCHING AUTHORITY
	; .		(PCT Rule 43bis.1)
		Date of mailing (day/month/year)	
Applicant's or agent's file reference			CTION
LEA36769-WO		FOR FURTHER A	See paragraph 2 below
	Ix a series of City of Asset		Priority date (day/month/year)
International application No.	International filing date (aay monin year)	02.07.2003
PCT/EP2004/006682	21.06.2004		02.07.2003
Applicant BAYER HEALTHCARE AG			· .
Box No. IV Lack of unit Box No. V Reasoned st applicability Box No. VI Certain doc Box No. VII Certain defe Box No. VIII Certain obse 2. FURTHER ACTION If a demand for international prelin laternational Preliminary Examining than this one to be the IPEA and the this International Searching Authority If this opinion is, as provided above.	shment of opinion with regity of invention statement under Rule 43bis. The citations and explanation uments cited exts in the international approximation on the international minary examination is manufactured to the international approximation of the internation of the international approximation of the internation of the international approximation of the internation of the international approximation of the international approxim	gard to novelty, inventy I(a)(i) with regard to a ns supporting such state plication and application and that this does not apply the International Burden on opinion of the IPEA before the expiration	I be considered to be a written opinion of the oly where the applicant chooses an Authority other cau under Rule 66.1bis(b) that written opinions of the applicant is invited to submit to the IPEA a of 3 months from the date of mailing of Form
	•		
Name and mailing address of the ISA/EP		Authorized officer	. *
Facsimile No.		Telephone No.	

Box	No. I Basis of this opinion
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
	This opinion has been established on the basis of a translation from the original language into the following language
	, which is the language of a translation furnished for the purposes of international search (under
	Rule 12.3 and 23.1(b)).
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
	a. type of material
	a sequence listing
	table(s) related to the sequence listing
	b. format of material
	in written format
	in computer readable form
	c. time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Additional comments:
	·
٠ ا	

Be	ox No. II Priority
1.	The following document has not yet been furnished:
	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).
	translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)). Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on
	the assumption that the relevant date in the claimed priority date.
2.	This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
3.	Additional observations, if necessary:
İ	

Box No. Il	II Non-establishment of opinior	with regard to novelty, inventive step and industrial applicability
	ions whether the claimed invention appared not been examined in respect of:	pears to be novel, to involve an inventive step (to be non obvious), or to be industrially
	the entire international application	
\boxtimes	claims Nos. 9 (industrial ap	plicability)
becaus	e:	
\boxtimes	the said international application, or the relate to the following subject matter w	said claims Nos. 9 nich does not require an international preliminary examination (specify):
		bject matter which, in the opinion of this
	Authority, falls unde	r PCT Rule 67.1(iv). Consequently, no expert
	opinion has been esta	blished in respect of the industrial
	applicability of the	subject matter of said claims (PCT Article
	34(4)(a)(i)).	`
	the description, claims or drawings (incare so unclear that no meaningful opinion	icate particular elements below) or said claims Nos. on could be formed (specify):
		•
		·
		,
	the claims, or said claims Nos. by the description that no meaningful o	are so inadequately supported pinion could be formed.
	no international search report has been	established for said claims Nos.
	the nucleotide and/or amino acid seque Instructions in that:	nce listing does not comply with the standard provided for in Annex C of the Administrative
	the written form	has not been furnished
		does not comply with the standard
		□
	the computer readable form	has not been furnished
		does not comply with the standard
		Vor amino acid sequence listing, if in computer readable form only, do not comply with the Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further detail	s.

International application No.
PCT/EP2004/006682

Box No. V	Reasoned statement citations and expla			novelty, inventive ste	p or industrial applicability;	:
1. Statement				•		
· Novelty (N)	Claims	1-9	·		YES
	,	Claims		 		NO
Inventive	step (IS)	Claims				YES
		Claims	1-9			NO.
Industrial	applicability (IA)	Claims	1-8	 		YES
	•	Claims				NO
				 	J	

2. Citations and explanations:

Prior art

Substantive examination has been carried out with account taken of the following documents, cited in the search report:

D1: WO 03/041712 A (SMITH STEPHEN ALLAN; LIDDLE JOHN (GB);
PINTO IVAN LEO (GB); FELL STEP) 22 May 2003
(2003-05-22)

D2: WO 00/66567 A (FENWICH ASHLEY EDWARD; SMITH STEPHEN ALLAN (GB); IFE ROBERT JOHN (GB)) 9 November 2000 (2000-11-09)

2. Novelty

Claims 1-9 meet the requirements of PCT Article 33(2): the compounds of the present claim 1 can be regarded as a novel selection over those from D1, owing to the 1,2,4-triazinone unit.

The said 1,2,4-triazinone unit also represents the distinguishing feature in relation to the compounds from D2.

3. Inventive step

The present application, however, does not meet the requirements of PCT Article 33(3).

International application No.
PCT/EP2004/006682

Box No. V

Reasoned statement under Rule 43bis.1(a)(l) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The problem of the present application can be seen as being that of providing further 1,2,4-triazinone derivatives suitable for the treatment of chronic-inflammatory diseases.

The closest prior art is represented by D1. D1 discloses structurally similar compounds having qualitatively equivalent properties, from which the present compounds represent only a novel selection.

Such a selection can only be regarded as being inventive if 'the selected compounds of the present application exhibit unexpected effects over the compounds from D1. However, no such effects have been described in the present application. In the absence of comparative data or other suitable information, it is not possible to assess whether this problem has been solved or not.

With regard to the process claim there is no discernible inventive feature.

Consequently, an inventive step cannot be acknowledged.

Patent No. (day/month/year) (day/month/year) (day/month/year) Patent No. (day/month/year) (day/month/year) (day/month/year) Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)	Certain published	documents (Rule 43bis. 1 and	70.10)		•
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)				Filing date (day/month/year)	Priority date (valid clain (day/month/year)
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)		•			
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)	•	•		•	
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)					•
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure (day/month/year) (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year)	•				
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)				•	
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)	•	•			
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)					
Non-written disclosures (Rule 43bis.1 and 70.9) Kind of non-written disclosure (day/month/year) Date of non-written disclosure referring to non-written disclosure (day/month/year) (day/month/year)	e supple	mental sheet			
Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)	o oupple				
Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)		•		•	
Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year) (day/month/year)					
Kind of non-written disclosure Date of non-written disclosure (day/month/year) Date of written disclosure referring to non-written disclosure (day/month/year)					
(day/month/year) (day/month/year)	Non-written discl	osures (Rule 43bis.1 and 70.9)			
	Non-written discl	osures (Rule 43bis.1 and 70.9)	•		
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ng to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ng to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
			Date of non-written di	isclosure referri	ig to non-written disclosure
		of non-written disclosure	Date of non-written di	isclosure referri	ig to non-written disclosure
		of non-written disclosure	Date of non-written di (day/month/yea	isclosure referri	ig to non-written disclosure
ee form 210		of non-written disclosure	Date of non-written di (day/month/yea	isclosure referri	ig to non-written disclosure
		of non-written disclosure	Date of non-written di (day/month/yea	isclosure referri	ig to non-written disclosure
		of non-written disclosure	Date of non-written di (day/month/yea	isclosure referri	ng to non-written disclosure

International application No.
PCT/EP2004/006682

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box VI

Reference is made to the following document:

- D3: WO 03/093268 A (ALONSO-ALIJA CRISTINA: BAYER AG (DE); BISCHOFF HILMAR (DE); BURKHARDT) 13 November 2003 (2003-11-13)
- D3 will be considered in any regional phase.

Form PCT/ISA/237 (Supplemental Box) (January 2004)